Search results
Results from the WOW.Com Content Network
A phase I clinical trial is recruiting individuals to study the side effects and efficacy of CD19/CD22 chimeric antigen receptor T cells (i.e. T-cells from a donor patent are obtained, engineered to attack cells that express CD19 or CD22, and then injected back into the donor) when given together with chemotherapy in treating patients with ...
Anti-CD19 immunotoxin is a monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD19 immunotoxin is made in the laboratory. It binds to CD19, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.
An anti-CD22 immunotoxin is a monoclonal antibody targeting CD22 linked to a cytotoxic agent. As of August 2009, it was studied in the treatment of some types of B-cell cancer. It binds to CD22, a receptor protein on the surface of normal B cells and B-cell tumors , and, upon internalization, kills the cells, acting as immunotoxin .
Splenic B-cell lymphoma/leukemia unclassifiable: The rare reports on this lymphoma find the monoclonal B cells to be CD19+, CD20+ (bright, CD23+, CD11+, CD25−, CD103−, CD72+, and annexin A1−. [18] These cells, similar to the monoclonal cells in Hairy cell leukemia, [19] may have the V600E mutation in the BRAF gene. Patients with this ...
CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. [4] It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases .
Duvortuxizumab (INN [1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies. [ 2 ] This drug was developed by Janssen Global Services.
CD19 has also been implicated in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, and may be a useful treatment target. [ 13 ] [ 16 ] [ 33 ] Mouse model research shows that CD19 deficiency can lead to hyporesponsiveness to transmembrane signals and weak T cell dependent humoral response , that in turn leads to an ...
The project publishes drug reports. The first three reports covered Statins to reduce high cholesterol, heartburn drugs, and NSAIDs commonly used to treat arthritis. The project covers over 20 conditions and the most widely used drugs. [5] The reports are published in web versions and two-page PDF summaries in English and Spanish.